- Home
- VRAX vs RMCO Comparison
VRAX vs RMCO Comparison
Compare VRAX & RMCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRAX
- RMCO
- Stock Information
- Founded
- VRAX 2013
- RMCO 2021
- Country
- VRAX United Kingdom
- RMCO United States
- Employees
- VRAX N/A
- RMCO N/A
- Industry
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- RMCO Multi-Sector Companies
- Sector
- VRAX Health Care
- RMCO Miscellaneous
- Exchange
- VRAX Nasdaq
- RMCO Nasdaq
- Market Cap
- VRAX 17.2M
- RMCO 17.2M
- IPO Year
- VRAX 2022
- RMCO N/A
- Fundamental
- Price
- VRAX $1.97
- RMCO $1.07
- Analyst Decision
- VRAX
- RMCO
- Analyst Count
- VRAX 0
- RMCO 0
- Target Price
- VRAX N/A
- RMCO N/A
- AVG Volume (30 Days)
- VRAX 4.9M
- RMCO 10.0K
- Earning Date
- VRAX 11-26-2024
- RMCO 11-22-2024
- Dividend Yield
- VRAX N/A
- RMCO N/A
- EPS Growth
- VRAX N/A
- RMCO N/A
- EPS
- VRAX N/A
- RMCO N/A
- Revenue
- VRAX $156,419.00
- RMCO $644,293.00
- Revenue This Year
- VRAX $5,169.18
- RMCO N/A
- Revenue Next Year
- VRAX $66.97
- RMCO N/A
- P/E Ratio
- VRAX N/A
- RMCO N/A
- Revenue Growth
- VRAX 1727.11
- RMCO 126.99
- 52 Week Low
- VRAX $0.60
- RMCO $0.70
- 52 Week High
- VRAX $9.00
- RMCO $5.90
- Technical
- Relative Strength Index (RSI)
- VRAX 46.98
- RMCO 53.62
- Support Level
- VRAX $1.92
- RMCO $1.04
- Resistance Level
- VRAX $2.50
- RMCO $1.19
- Average True Range (ATR)
- VRAX 0.22
- RMCO 0.08
- MACD
- VRAX 0.01
- RMCO 0.00
- Stochastic Oscillator
- VRAX 26.97
- RMCO 57.14
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.
About RMCO Royalty Management Holding Corporation
Royalty Management Holding Corp formed to invest or purchase assets that have current or near-term income to provide the company with accretive cash flow from which it can reinvest in new assets or expand cash flow from existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.